Puerto Rico Opens Research and Development Center for Pharmaceutical Products - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Puerto Rico Opens Research and Development Center for Pharmaceutical Products



The Puerto Rico Industrial Development Company and governor Alejandro García Padilla had an inauguration ceremony for Neolpharma's new Development and Innovation Center (CEDIPROF) for pharmaceutical products in Puerto Rico.

In 2013, Neolpharma invested over $12 million in machinery and equipment in the center in Puerto Rico. The center will create 23 new jobs. CEDIPROF includes a 2000 ft2 pilot facility for research, development, and evaluation of new pharmaceutical products, as well as an analytic and forensic laboratory and a 4000 ft2 warehouse.

Source: Puerto Rico Industrial Development Company

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here